Gabapentin for the Treatment of Vulvodynia: A Randomized Controlled Trial.

ABSTRACT:

Objective

To evaluate whether extended-release gabapentin is more effective than placebo among women with vulvodynia.

Methods

In a multicenter double-blind, placebo-controlled randomized crossover trial, gabapentin (1,200-3,000 mg/d) was compared with a placebo. The primary outcome was mean pain intensity (0, no pain at all to 10, worst pain ever) on the tampon test (a standardized tampon insertion and removal test used as a surrogate marker for dyspareunia) during the last 7 days of the maintenance phase. Secondary outcomes included sexual intercourse pain and daily pain. A sample size of 53 provided 90% power to detect a 1-point reduction on the tampon test (.05 level, two-sided) between the two treatment phases.

Results

From August 2012 to January 2016, 230 women w

SUBMITTER: Brown CS 

PROVIDER: S-EPMC6020139 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature